Mesoangioblast
Mesoangioblasts are a type of stem cell that are progenitors of vascular and muscle cells. These cells have been identified as playing a crucial role in the regeneration of damaged muscle tissue and are considered a promising avenue for the treatment of muscular dystrophy and potentially other muscle-related diseases. Mesoangioblasts originate from the mesoderm, the middle layer of embryonic development, which gives rise to the circulatory system, muscle, and bone.
Characteristics[edit | edit source]
Mesoangioblasts are distinguished by their ability to differentiate into various cell types associated with the vascular system and skeletal muscle. They express markers such as CD34, Sca-1, and alkaline phosphatase, which are indicative of their stem cell nature and their potential to contribute to muscle regeneration. These cells can be isolated from small blood vessels, particularly the aorta, and have been shown to migrate across vessel walls to reach and repair damaged muscle tissue.
Therapeutic Potential[edit | edit source]
The therapeutic potential of mesoangioblasts lies in their capacity to regenerate muscle tissue, making them a target for cell-based therapies in muscular dystrophies, a group of genetic diseases characterized by progressive muscle weakness and degeneration. Studies have demonstrated that when transplanted into animal models of muscular dystrophy, mesoangioblasts can contribute to muscle repair and improve muscle function. Clinical trials are ongoing to evaluate the safety and efficacy of mesoangioblast transplantation in humans with Duchenne Muscular Dystrophy (DMD), one of the most severe forms of muscular dystrophy.
Challenges and Future Directions[edit | edit source]
While mesoangioblasts offer a promising therapeutic avenue, there are several challenges to their clinical application. These include optimizing the delivery methods to target muscles, enhancing the survival and integration of transplanted cells into host tissue, and avoiding immune rejection. Future research is focused on addressing these challenges, improving the efficiency of mesoangioblast transplantation, and exploring the potential of these cells in treating other diseases characterized by vascular and muscle damage.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
